Kite

News story on Seeking Alpha:

Jefferies’ Biren Amin likes Kite Pharma (NASDAQ:KITE). He says a recent survey on the non-Hodgkin lymphoma landscape is bullish for Kite’s Axi-cel in 2018 and 2019. Respondents indicated that 30 - 40% of second-line patients will be treated with Axi-cel in the two years (BUY/$101)

6 Likes

New to the board, glanced over the KB. Do you feel Bullish on KITE due to these news?